Aprepitant for the treatment of refractory pruritus in patients with primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.

Trial Profile

Aprepitant for the treatment of refractory pruritus in patients with primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top